EP101/#503 Relevance of Genomic Instability Score, Tumor Mutational Burden, and Tumor Infiltrating Lymphocytes As Biomarkers in Uterine Serous Carcinoma
E-Posters(2022)
摘要
Objectives Uterine serous carcinomas (USC) represent 10% of endometrial carcinomas but nearly 40% of deaths. We characterized genomic instability (GIS), tumor mutational burden (TMB), and density of tumor infiltrating lymphocytes (TILs) in patients with USC. Methods A single institution, retrospective cohort study analyzed patients with USC following hysterectomy. In collaboration with Myriad Genetics, we determined GIS score and TMB from archived specimens. Cox proportional hazards models evaluated associations of molecular factors with survival. Using immunohistochemistry, we evaluated tumoral expression of CD3, CD4, CD8. T-tests were conducted to evaluate associations of TILs with GIS and tumor recurrence. Results We evaluated 53 patients with USC; 66% (n=35/53) presented with advanced disease (stage III-IV). Median GIS was 31 (range: 0–52) and not associated progression-free survival (PFS) or overall survival (OS). Median TMB was 1.35; patients whose tumors exhibited TMB >1.35mutations/megabase (median) had improved PFS and OS (p=0.005, 0.002). Two tumors had elevated CD3+ TILs (>75th percentile) and low GIS (<=31). Tumors with elevated CD3+ and CD4+ immune cells had significantly higher mean GIS (p=0.013, p=0.002). Tumors with both low GIS and low-normal TILs (<=75th percentile) had lower recurrence rates (p=0.2). Conclusions TMB >1.35 mutations/megabase was associated with improved survival. Alternate TMB thresholds may provide prognostic value for less immunogenic tumors, like USC. In this limited data set, GIS was not associated with survival or recurrence. Patients with low GIS and low-normal TIL infiltration had lower recurrence rates, unlike other solid tumors. Additionally, the presence of CD3/CD4+ immune cells may be a marker of GIS.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn